he beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.

Bibliographic Details
Title: he beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.
Authors: Hong Shen, Rui Min, Qi Tan, Weiping Xie, Hong Wang, Hongqiu Pan, Li Zhang, Hongtao Xu, Xia Zhang, Jianzhong Dai
Source: Archives of Medical Science; Jun2015, Vol. 11 Issue 3, p584-590, 7p
Subject Terms: TUBERCULOSIS treatment, TUBERCULOSIS patients, MULTIDRUG resistance, RECOMBINANT molecules, INTERLEUKIN-2, CANCER chemotherapy
Abstract: Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a hard-to-treat disease with a poor outcome of chemotherapy. In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB. Material and methods: Fifty culture-confirmed patients with MDR-TB were included. Twenty-five patients were randomly assigned to the trial group (injection of 500 000 IU of rhIL-2 once every other day at the first, third, fifth and seventh months in addition to standard multidrug therapy) and another 25 patients to the control group with standard multidrug therapy. All patients were monitored clinically, and T-cell subsets were analyzed by flow cytometry. Results: The rates of sputum negative conversion and X-ray resolution in the trial group were higher than those of the control, and the improvements were significant by completion of treatment. In addition, CD4+CD25+ T cells in the controls rose gradually during treatment. The levels at the end of the seventh month were significantly higher than before, which were also significantly different when compared with those from the trial group at the same time. However, there were no such changes associated with treatment in the trial group. No significant differences appeared in other T cell subsets. Conclusions: Exogenous IL-2 in the present regimen improves immunity status. Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB. [ABSTRACT FROM AUTHOR]
Copyright of Archives of Medical Science is the property of Termedia Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:17341922
DOI:10.5114/aoms.2015.52362
Published in:Archives of Medical Science
Language:English